# A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)

> **NCT05879744** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Cullinan Therapeutics Inc.** · enrollment: 90 (estimated)

## Conditions studied

- NHL
- NHL, Relapsed, Adult

## Interventions

- **DRUG:** CLN-978

## Key facts

- **NCT ID:** NCT05879744
- **Lead sponsor:** Cullinan Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-31
- **Primary completion:** 2026-11
- **Final completion:** 2027-04
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05879744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05879744, "A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05879744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*